Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX®(Pitolisant) in Pediatric Patients with Narcolepsy

PLYMOUTH MEETING, Pa.June 24, 2024 /PRNewswire/ — Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric patients (6 to <18 years of age) with narcolepsy.

Check out the full article here or the PDF version here.